For the first time, cyclin‐dependent kinase inhibitor 2A (commonly abbreviated as p16) status and extracapsular spread (ECS) began to play an important role in the new tumor classification for OPSCC [4, 5]. This evidence concerns the gene CDKN2A and neoplasm.